Therapeutic prospects for PEDF: More than a promising angiogenesis inhibitor

Research output: Contribution to journalArticlepeer-review

88 Scopus citations

Abstract

Blood vessel growth and stability are under the exquisite control of a network of pro- and anti-angiogenic factors. Disruption of the balance between these factors is a characteristic of tumor growth and many vascular diseases. Endogenous angiogenesis inhibitors, particularly those that act broadly at the earliest stages, could be excellent pharmacological tools in combating pathogenic vessel growth. Pigment-epithelium-derived factor (PEDF) is a natural angiogenesis inhibitor that (1) targets only new vessel growth, (2) can be administered therapeutically as a soluble protein or by viral-mediated gene transfer, (3) is stable and nontoxic when injected, and (4) is more potent than other well-characterized angiogenesis inhibitors. Because PEDF also has differentiating and neuroprotective activities, it has additional benefits for use in the nervous system. The production of PEDF by many tissues suggests its therapeutic potential should be explored in a much wider range of diseases, including tumor proliferation and metastasis.

Original languageEnglish (US)
Pages (from-to)244-250
Number of pages7
JournalTrends in Molecular Medicine
Volume9
Issue number6
DOIs
StatePublished - Jun 1 2003

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology

Fingerprint Dive into the research topics of 'Therapeutic prospects for PEDF: More than a promising angiogenesis inhibitor'. Together they form a unique fingerprint.

Cite this